PARIS--(BUSINESS WIRE)-- BioAlliance Pharma SA (Paris:BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, today announced the reinforcement of its Supervisory Board following the latter's renewal at the April 29th General Shareholders' Meeting. The Supervisory Board of 6 members is committed to supporting the company's growth. Four members are coming from pharmaceutical or specialty pharma companies and two from the financial world.
